Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1978-9-25
|
| pubmed:abstractText |
A stimulatory luteinizing hormone-releasing hormone (LRH) analogue D-Ser(TBU)6-EA10-LRH was administered subcutaneously once daily in a dose of 5 microgram to four regularly menstruating women. Treatment was instituted within the first three days of the menstrual bleeding and continued for 22--30 days. Ovulation was inhibited in all the women during the treatment cycle. The treatment resulted in disturbances in the pituitary gonadotropin secretion which presumably led to disordered follicular menuration and anovulation. The maximum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) responses to the LRH analogue were obtained during the first few days of treatment. The gonadotropin responses then rapidly decreased during the prolonged treatment. This change in the pituitary responsiveness probably prevented the release of a normal preovulatory LH surge. After the treatment, all the women resumed normal ovulatory menstrual cycles. The results suggest that it might be possible to use stimulatory LRH analogues for birth control.
|
| pubmed:keyword |
http://linkedlifedata.com/resource/pubmed/keyword/Biology,
http://linkedlifedata.com/resource/pubmed/keyword/Clinical Research,
http://linkedlifedata.com/resource/pubmed/keyword/Contraception,
http://linkedlifedata.com/resource/pubmed/keyword/Contraception Research,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Mode Of Action,
http://linkedlifedata.com/resource/pubmed/keyword/Endocrine System,
http://linkedlifedata.com/resource/pubmed/keyword/Estradiol--analysis,
http://linkedlifedata.com/resource/pubmed/keyword/Estrogens,
http://linkedlifedata.com/resource/pubmed/keyword/Family Planning,
http://linkedlifedata.com/resource/pubmed/keyword/Female Contraception,
http://linkedlifedata.com/resource/pubmed/keyword/Follicle Stimulating...,
http://linkedlifedata.com/resource/pubmed/keyword/Gonadotropins,
http://linkedlifedata.com/resource/pubmed/keyword/Gonadotropins, Pituitary,
http://linkedlifedata.com/resource/pubmed/keyword/Hormones,
http://linkedlifedata.com/resource/pubmed/keyword/Human Volunteers,
http://linkedlifedata.com/resource/pubmed/keyword/Injectables,
http://linkedlifedata.com/resource/pubmed/keyword/Luteinizing Hormone--analysis,
http://linkedlifedata.com/resource/pubmed/keyword/Menstrual Cycle,
http://linkedlifedata.com/resource/pubmed/keyword/Ovulation Suppression,
http://linkedlifedata.com/resource/pubmed/keyword/Physiology,
http://linkedlifedata.com/resource/pubmed/keyword/Pituitary Hormone Releasing...,
http://linkedlifedata.com/resource/pubmed/keyword/Progestational Hormones,
http://linkedlifedata.com/resource/pubmed/keyword/Progesterone--analysis,
http://linkedlifedata.com/resource/pubmed/keyword/Research Methodology
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0010-7824
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
537-45
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:otherAbstract |
PIP: 4 women aged 30-34 years were given the luteinizing hormone-releasing hormone (LH-RH) analog D-Ser(TBU6-EA10-LRH to determine its effects on the pituitary response. 5 mcg/day analog were self-administered sc for 22-30 days beginning within the first 3 days of menstrual bleeding, and serum follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and progesterone were monitored 3 times weekly. In all 4 subjects there was a sharp rise in LH and FSH on Treatment Day 1 that fell to within lower normal follicular phase limits for the remainder of treatment. Estradiol and progesterone responses varied among the subjects, perhaps because premature bleeding caused 2 subjects to begin treatment at a different point in the menstrual cycle. 1 subject stopped treatment after Day 22 because of headache and vertigo. None of the women ovulated during treatment, but 3 of 4 had ovulated within 4 weeks of discontinuation of treatment, and all women ovulated in the following cycle. The anovulatory effect of the analog is thought to be due to a disturbance of pituitary gonadotropin secretion that leads in turn to disordered follicle development. The possibilities for using this analog as a means of birth control are discussed.
|
| pubmed:meshHeading |
pubmed-meshheading:352612-Adult,
pubmed-meshheading:352612-Amenorrhea,
pubmed-meshheading:352612-Family Planning Services,
pubmed-meshheading:352612-Female,
pubmed-meshheading:352612-Follicle Stimulating Hormone,
pubmed-meshheading:352612-Gonadotropin-Releasing Hormone,
pubmed-meshheading:352612-Humans,
pubmed-meshheading:352612-Luteal Phase,
pubmed-meshheading:352612-Luteinizing Hormone,
pubmed-meshheading:352612-Menstruation,
pubmed-meshheading:352612-Ovulation,
pubmed-meshheading:352612-Time Factors
|
| pubmed:year |
1978
|
| pubmed:articleTitle |
Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?
|
| pubmed:publicationType |
Journal Article
|